CN Patent

CN117580579A — 用于治疗儿科患者的癫痫发作病症的方法和组合物

Assigned to Shenzhen Kangzhe Biotechnology Co ltd · Expires 2024-02-20 · 2y expired

What this patent protects

提供用于鼻内递送苯二氮卓类、如地西泮、咪达唑仑和劳拉西泮的组合物和其用于治疗和预防2‑5岁(包含端值)的儿科受试者的癫痫发作的方法。提供在施用之后降低副作用的发生率和/或严重程度的用于快速治疗发作的组合物以及改善患者对处方治疗方案的依从性的方法。

USPTO Abstract

提供用于鼻内递送苯二氮卓类、如地西泮、咪达唑仑和劳拉西泮的组合物和其用于治疗和预防2‑5岁(包含端值)的儿科受试者的癫痫发作的方法。提供在施用之后降低副作用的发生率和/或严重程度的用于快速治疗发作的组合物以及改善患者对处方治疗方案的依从性的方法。

Drugs covered by this patent

Patent Metadata

Patent number
CN117580579A
Jurisdiction
CN
Classification
—
Expires
2024-02-20
Drug substance claim
No
Drug product claim
No
Assignee
Shenzhen Kangzhe Biotechnology Co ltd
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.